SYNCOM FORMULATIONS (INDIA)
Back to Balance Sheet
|
SYNCOM FORMULATIONS (INDIA) Last 5 Year Total Current Liabilities History
[Consolidated]
Mar2024 | Mar2023 | Mar2022 | Mar2017 | Mar2016 | |
---|---|---|---|---|---|
Total Current Liabilities | ₹107 Cr | ₹113 Cr | ₹78 Cr | ₹59 Cr | ₹66 Cr |
What is the latest Total Current Liabilities ratio of SYNCOM FORMULATIONS (INDIA) ?
Year | Total Current Liabilities |
---|---|
Mar2024 | ₹107 Cr |
Mar2023 | ₹113 Cr |
Mar2022 | ₹78 Cr |
Mar2017 | ₹59 Cr |
Mar2016 | ₹66 Cr |
How is Total Current Liabilities of SYNCOM FORMULATIONS (INDIA) Trending?
Years | Total Current Liabilities | % Change | |
---|---|---|---|
Mar2024 | ₹107 Cr | -5.86 | |
Mar2023 | ₹113 Cr | 44.60 | |
Mar2022 | ₹78 Cr | 33.01 | |
Mar2017 | ₹59 Cr | -10.43 | |
Mar2016 | ₹66 Cr | - |
Compare Total Current Liabilities of peers of SYNCOM FORMULATIONS (INDIA)
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
SYNCOM FORMULATIONS (INDIA) | ₹2,084.0 Cr | 4.7% | 34.5% | 82.8% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹405,824.0 Cr | 0.5% | -0.5% | 14.6% | Stock Analytics | |
DIVIS LABORATORIES | ₹178,355.0 Cr | 1.3% | 10.7% | 49.3% | Stock Analytics | |
CIPLA | ₹122,929.0 Cr | 2.2% | 0.2% | 2.3% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹112,701.0 Cr | 4.7% | 11.9% | 14.5% | Stock Analytics | |
TORRENT PHARMACEUTICALS | ₹108,502.0 Cr | 2% | -0.8% | 15.7% | Stock Analytics |
SYNCOM FORMULATIONS (INDIA) Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
SYNCOM FORMULATIONS (INDIA) | 4.7% |
34.5% |
82.8% |
SENSEX | 1.9% |
0.1% |
10.9% |
You may also like the below Video Courses